Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Dirk Jäger

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5006080186, A5113602946. Sources: ClinicalTrials.gov.

Their work

Papers
39 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: 4 papers · 2013: 5 papers · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 7 papers · 2022: 4 papers · 2023: 3 papers · 2024: 1 paper

Papers 39

  1. Effects of parenteral nutrition + best supportive nutritional care vs. best supportive nutritional care alone on quality of life in patients with pancreatic ca… Co-author DOI 10.1007/s00520-024-08666-1↗
  2. Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005481↗
  3. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… Co-author DOI 10.1111/cts.13661↗
  4. Sex Differences in the Systemic and Local Immune Response of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers15061815↗
  5. Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2022.2027148↗
  6. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Co-author DOI 10.1097/sla.0000000000004147↗
  7. Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. Co-author DOI 10.3389/fimmu.2022.1096162↗
  8. Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.947407↗
  9. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. Co-author DOI 10.1002/gcc.22932↗
  10. MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Co-author DOI 10.1016/j.omto.2021.04.015↗
  11. Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic… Co-author DOI 10.1080/2162402x.2021.1962135↗
  12. Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer Co-author DOI 10.1101/2021.03.13.435100↗
  13. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects. Co-author DOI 10.1136/jitc-2021-002505↗
  14. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-21-1020↗
  15. Perioperative changes in the plasma metabolome of patients receiving general anesthesia for pancreatic cancer surgery. Co-author DOI 10.18632/oncotarget.27956↗
  16. [Neoadjuvant and adjuvant treatment of pancreatic cancer]. Co-author DOI 10.1007/s00104-020-01169-9↗
  17. Chemotherapy for pancreatic cancer. First author DOI 10.1016/j.lpm.2019.02.025↗
  18. Optimizing the outcomes of pancreatic cancer surgery. Co-author DOI 10.1038/s41571-018-0112-1↗
  19. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative ch… Co-author DOI 10.1136/bmjopen-2018-028696↗
  20. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  21. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrosp… Co-author DOI 10.1016/j.pan.2017.04.012↗
  22. Pancreatic Cancer Surgery: The New R-status Counts. Co-author DOI 10.1097/sla.0000000000001731↗
  23. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older… Co-author DOI 10.1186/s12876-017-0709-3↗
  24. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pan… Co-author DOI 10.1186/s12885-017-3604-y↗
  25. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Co-author DOI 10.1097/sla.0000000000001850↗
  26. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Co-author DOI 10.1038/bjc.2015.72↗
  27. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-015-0560-3↗
  28. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Disea… Co-author DOI 10.1016/j.pan.2014.03.004↗
  29. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. Co-author DOI 10.1245/s10434-014-3607-8↗
  30. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma. Co-author DOI 10.3390/ijms15034104↗
  31. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comp… Co-author DOI 10.1007/s00066-013-0391-5↗
  32. Improvement of surgical results for pancreatic cancer. Co-author DOI 10.1016/s1470-2045(13)70172-4↗
  33. Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma. Co-author DOI 10.1159/000356811↗
  34. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. Co-author DOI 10.1186/1471-2407-13-419↗
  35. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Co-author DOI 10.1245/s10434-012-2762-z↗
  36. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Co-author DOI 10.1016/j.surg.2012.05.029↗
  37. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Co-author DOI 10.1093/annonc/mdr379↗
  38. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. Co-author DOI 10.1097/cji.0b013e31824b3a76↗
  39. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with r… Co-author DOI 10.1200/jco.2011.38.2960↗

Trials 1

  1. Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer Principal investigator NCT01362582↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christoph Springfeld · 21 shared papers, 2013–2023 · strength 2.12
  2. Thilo Hackert · 15 shared papers, 2012–2023 · strength 1.70
  3. Markus Wolfgang Büchler · 18 shared papers, 2012–2023 · strength 1.36
  4. Niels Halama · 8 shared papers, 2017–2023 · strength 1.01
  5. Azaz Ahmed · 6 shared papers, 2021–2023 · strength 0.88
  6. Nathalia A. Giese · 5 shared papers, 2021–2023 · strength 0.74
  7. Rosa Klotz · 5 shared papers, 2021–2023 · strength 0.74
  8. Oliver Strobel · 8 shared papers, 2012–2023 · strength 0.73
  9. John P. Neoptolemos · 4 shared papers, 2019–2021 · strength 0.53
  10. Christine E. Engeland · 4 shared papers, 2017–2022 · strength 0.41
  11. Guy Ungerechts · 4 shared papers, 2017–2022 · strength 0.41
  12. Anne Katrin Berger · 5 shared papers, 2014–2021 · strength 0.40
  13. Albrecht Stenzinger · 4 shared papers, 2017–2023 · strength 0.39
  14. Jens Werner · 9 shared papers, 2012–2018 · strength 0.38
  15. Thomas P. Hank · 3 shared papers, 2017–2023 · strength 0.37
  16. Nicolas Hohmann · 3 shared papers, 2021–2023 · strength 0.35
  17. Hans Martin Singh · 3 shared papers, 2017–2021 · strength 0.33
  18. Jürgen Debus · 8 shared papers, 2012–2015 · strength 0.30
  19. Jacek Hajda · 3 shared papers, 2017–2023 · strength 0.29
  20. Jens Thomas Siveke · 2 shared papers, 2021–2023 · strength 0.28
  21. Martin Ronald Sprick · 3 shared papers, 2017–2023 · strength 0.27
  22. Andreas Trumpp · 3 shared papers, 2017–2023 · strength 0.27
  23. Ulla Klaiber · 2 shared papers, 2019–2023 · strength 0.27
  24. Aline Emanuel · 1 shared paper, 2024 · strength 0.24
  25. Ingeborg Rötzer · 1 shared paper, 2024 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.